Steven Grant, MD, Virginia Commonwealth University

Steven Grant, MD
Steven Grant, MD

The Grant laboratory specializes on treatments or leukemia by targeting a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. Their research is dedicated to cellular and molecular events that govern cancer cell behavior.



  1. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15;17(10):3219-32.